Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Retrospective Effectiveness Study of Dalbavancin and Other Standard of Care of the Same Class (i.v. Lipo and Glyco-peptides) in Patients With ABSSSI

NCT04298463 is registered in ClinicalTrials.gov with Aziende Chimiche Riunite Angelini Francesco S.p.A as lead sponsor.

NCT NCT04298463
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04298463 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Retrospective Effectiveness Study of Dalbavancin and Other Standard of Care of the Same Class (i.v. Lipo and Glyco-peptides) in Patients With ABSSSI
Lead sponsor
Aziende Chimiche Riunite Angelini Francesco S.p.A
Phase
Observational
Overall status
Completed
Start date
June 18, 2020
Completion date
May 19, 2021
Enrollment
184 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

acute bacterial skin and skin structure infection